GTCbio, San Diego, CA
Oct. 18-19, 2004
The human morbidity and mortality are largely dependent on the ever-elusive world of drug discovery and development. Over the past few years, there has been an explosion of scientific and clinical advances, both within chemical and biological driven areas. Consequently, this new wave of interdisciplinary technology has led to the identification and in vivo validation of new drug targets. In addition, to the discovery of new small molecule and protein based therapeutic agents for major forms of human diseases. In this regard, GTCbio is holding an annual conference on “Modern Drug Discovery and Development” on October 18-19, 2004 in San Diego, CA.This event will be organized into five sessions: I. Drug design and lead optimization; II. Biological Processes and Process Development; III. Metabolic and Toxicological Processes; IV. Biological Products, Chemical and Biological Information, and V. Proteomics and Pharmacogenomics. A total of 27 speakers have been confirmed to present at this two-day event. Presenting companies include industry-leaders such as Merck, Schering-Plough, Boehringer Ingelheim GmbH, Johnson & Johnson, Aventis Pharmaceuticals, Novartis Research Foundation, IBM Life Sciences, and many more. “Modern Drug Discovery & Development” will deliver the information you need to stay up to speed, as the meeting will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. Specifically, it is suitable for Research Investigators, Group Leaders, Vice Presidents, Directors, Project Managers, Manufacturers, Presidents of R&D, Medical Directors, Global Project Managers, Marketers and Venture Capitalists. In addition, the event will provide a great opportunity for companies to expose products and services. Networking times have been allocated to enhance the exchange of information between technology developers and end-users.
|
|
Invited Speakers:
|
|
Daniel Wyss Schering-Plough Research InstituteGuenter Trummlitz Boehringer Ingelheim GmbH James Guy Breitenbucher Johnson & Johnson PRD Reinhold Tacke Institute fur Anorganische Chemie Sophie-Dorothee Clas Merck Frosst Canada & Co. Rainer Netzer Evotech OAI Amy Rubinstein Zygogen LLC Dr. Dale Dhanoa Predix Pharmaceuticals Ivan Rich HemoGenix LLC James Kang Univ. of Louisville School of Medicine John Cashman Human BioMolecular Research Institute Chris King Merck & Co. Fraser Wright Avigen Inc. Howard Kaufman Columbia Univ. College of Physicians & Surgeons Leodevico Ilag Xerion Pharmaceuticals AG Pierre Beauparlant Gemin X Biotechnologies Inc David Edwards Accelrys Inc. Joseph D’Antuono ROW2 Technologies Inc. Mariana Vaschetto Accelrys Cambridge LTD Peter Gund IBM Life Sciences Pharmaceutical R&D Solutions Ilya Kupershmidt Silicon Genetics Ruben Abagyan Genomics Institute of the Novartis Research Foundation
|
|